Saturday 5 January, 2008

Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel


Daiichi Sankyo Company, Limited and Eli Lilly and Company today announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application for prasugrel to the USFDA. Prasugrel is an oral antiplatelet agent, initially in development for the treatment of patients with acute coronary syndrome who are managed with percutaneous coronary intervention (PCI), including coronary stenting.
If approved for marketing in the United States, the trade name for prasugrel will be Effient company officials added."We are elated," said J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for prasugrel. "We feel confident in the strength and completion of this submission package, and plan to complete our submission in Europe in the first quarter of 2008. The benefit/risk profile of this compound, in comparison with the current standard of care, has the potential to improve outcomes for ACS patients undergoing PCI."

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker